THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHETER; THERMOCOOL SMARTTOUCH UNI-DIRECTIONAL NAVIGATION CATHETER
Biosense Webster, Inc. · Decision date Sep 15, 2026
What did the FDA decide?
This 30-Day Notice records a process change for the THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHETER and THERMOCOOL SMARTTOUCH UNI-DIRECTIONAL NAVIGATION CATHETER. The stated change is "an additional supplier for critical components." The notice does not identify which components, the supplier, or the manufacturing step affected.
The supplement is classified as a Process Change involving Manufacturer/Sterilizer/Packager/Supplier. It is not a new approval of the catheter system, and the database statement does not provide evidence of safety or clinical effectiveness. Specific information about the component, supplier identity, and qualification status is absent from the source fields.
FDA approval order statement
an additional supplier for critical components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 15, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040036/S101
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- LPB
- Decision code
- OK30
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Biosense Webster, Inc.
- Product code
- LPB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040036. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040036 · Original PMA
NAVISTAR THERMOCOOL DEFLECTABLE DIAGNOSTIC/ABLATION CATHETER
P040036/S101 received
Application receipt date recorded by FDA.
P040036/S101 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P040036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Aug 11, 2006 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
| Irvine Biomedical, Inc. | PMA approval | Jan 14, 2005 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P040036/S101
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records